Literature DB >> 17916995

The cytoplasmic expression of MUC1 in papillary thyroid carcinoma of different histological variants and its correlation with cyclin D1 overexpression.

Alexander Abrosimov1, Vladimir Saenko, Serik Meirmanov, Masahiro Nakashima, Tatiana Rogounovitch, Olesya Shkurko, Eugeny Lushnikov, Norisato Mitsutake, Hiroyuki Namba, Shunichi Yamashita.   

Abstract

This study addressed the immunohistochemical expression of MUC1 in papillary thyroid carcinoma (PTC) of different histotypes, sizes, and morphological features of aggressiveness, and its correlation with the overexpression of cyclin D1, a target molecule of the Wnt pathway. MUC1 expression was examined in a total of 209 PTCs. Cytoplasmic MUC1 expression was elevated in the tall, columnar cell and oncocytic variants (100%), Warthin-like (78%), and conventional PTCs (61%), and in papillary microcarcinoma (PMC) with the conventional growth pattern (52%). On the contrary, it was low in the follicular variant (27%) of PTC and PMCs with follicular architecture (13%). Cytoplasmic MUC1 accumulation did not associate with any clinicopathological features except peritumoral lymphoid infiltration in PTCs and in PMCs with the conventional growth pattern. MUC1 staining correlated with cyclin D1 overexpression in conventional PTCs and PMCs and PMCs with follicular architecture. The results demonstrate that MUC1 expression varies broadly in different histological variants of PTC, being the lowest in tumors with follicular structure. In general, it does not prove to be a prognosticator of PTC aggressiveness. A high correlation between MUC1 and cyclin D1 implies MUC1 involvement in the Wnt cascade functioning in a large subset of human PTCs and PMCs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916995     DOI: 10.1007/s12022-007-0012-x

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  28 in total

1.  Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.

Authors:  Gaetano Magro; Monica Schiappacassi; Daniela Perissinotto; Antonella Corsaro; Cinzia Borghese; Antonino Belfiore; Alfonso Colombatti; Sebastiano Grasso; Carlo Botti; Emilio Bombardieri; Roberto Perris
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

2.  Cyclin D1 overexpression in thyroid papillary microcarcinoma: its association with tumour size and aberrant beta-catenin expression.

Authors:  D Lantsov; S Meirmanov; M Nakashima; H Kondo; V Saenko; Y Naruke; H Namba; M Ito; A Abrosimov; E Lushnikov; I Sekine; Sh Yamashita
Journal:  Histopathology       Date:  2005-09       Impact factor: 5.087

3.  MUC1 mucin gene, transcripts, and protein in adenomas and papillary carcinomas of the thyroid.

Authors:  I Bièche; E Ruffet; A Zweibaum; F Vildé; R Lidereau; B Franc
Journal:  Thyroid       Date:  1997-10       Impact factor: 6.568

4.  MUC1 plays a role in tumor maintenance in aggressive thyroid carcinomas.

Authors:  Kepal N Patel; Ellie Maghami; Volkert B Wreesmann; Ashok R Shaha; Jatin P Shah; Ronald Ghossein; Bhuvanesh Singh
Journal:  Surgery       Date:  2005-12       Impact factor: 3.982

Review 5.  Signal transduction of beta-catenin.

Authors:  B M Gumbiner
Journal:  Curr Opin Cell Biol       Date:  1995-10       Impact factor: 8.382

6.  Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations.

Authors:  Zhaowen Zhu; Manoj Gandhi; Marina N Nikiforova; Andrew H Fischer; Yuri E Nikiforov
Journal:  Am J Clin Pathol       Date:  2003-07       Impact factor: 2.493

7.  Papillary Hürthle cell carcinoma with lymphocytic stroma. "Warthin-like tumor" of the thyroid.

Authors:  R L Apel; S L Asa; V A LiVolsi
Journal:  Am J Surg Pathol       Date:  1995-07       Impact factor: 6.394

Review 8.  Cell signaling through membrane mucins.

Authors:  Kermit L Carraway; Victoria P Ramsauer; Bushra Haq; Coralie A Carothers Carraway
Journal:  Bioessays       Date:  2003-01       Impact factor: 4.345

Review 9.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

10.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components.

Authors:  J Wesseling; S W van der Valk; H L Vos; A Sonnenberg; J Hilkens
Journal:  J Cell Biol       Date:  1995-04       Impact factor: 10.539

View more
  8 in total

1.  Comparison of the clinicopathological behavior of the follicular variant of papillary thyroid carcinoma and classical papillary thyroid carcinoma: A systematic review and meta-analysis.

Authors:  Jing Yang; Yanping Gong; Shuping Yan; Qingquan Shi; Jingqiang Zhu; Zhihui Li; Qiang Chen; Rixiang Gong
Journal:  Mol Clin Oncol       Date:  2015-04-06

2.  Muc-1 expression may help characterize thyroid nodules but does not predict patients' outcome.

Authors:  Elaine Cristina Morari; Joyce Rosário Silva; Ana Carolina Trindade Guilhen; Lucas Leite Cunha; Marjory Alana Marcello; Fernando Augusto Soares; José Vassallo; Laura Sterian Ward
Journal:  Endocr Pathol       Date:  2010-12       Impact factor: 3.943

3.  Expression of MUC1 and CD176 (Thomsen-Friedenreich antigen) in papillary thyroid carcinomas.

Authors:  Xiang-xiang Zhan; Bing Zhao; Chang Diao; Yi Cao; Ruo-chuan Cheng
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

4.  Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin.

Authors:  Anna Batistatou; Konstantinos Charalabopoulos; Yukihiro Nakanishi; Constantine Vagianos; Setsuo Hirohashi; Niki J Agnantis; Chrissoula D Scopa
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 5.  Molecular markers of aggressiveness of thyroid cancer.

Authors:  Matthew D Ringel
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-10       Impact factor: 3.243

Review 6.  The Genetics of Papillary Microcarcinomas of the Thyroid: Diagnostic and Prognostic Implications.

Authors:  Ana Cunha Rodrigues; Gustavo Penna; Elisabete Rodrigues; Patrícia Castro; Manuel Sobrinho-Simões; Paula Soares
Journal:  Curr Genomics       Date:  2017-06       Impact factor: 2.236

7.  Clinical effect of MUC1 and its relevance to BRAF V600E mutation in papillary thyroid carcinoma: a case-control study.

Authors:  Quan Li; Wen-Xu Jin; Yi-Xiang Jin; Zhou-Ci Zheng; Xiao-Fen Zhou; Qing-Xuan Wang; Dan-Rong Ye; Yi-Han Sun; Xiao-Hua Zhang; Ou-Chen Wang; En-Dong Chen; Ye-Feng Cai
Journal:  Cancer Manag Res       Date:  2018-05-29       Impact factor: 3.989

Review 8.  Emerging Biomarkers in Thyroid Practice and Research.

Authors:  Shipra Agarwal; Andrey Bychkov; Chan-Kwon Jung
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.